HOW TO INTRODUCE A NEW TB VACCINE IN ADOLESCENTS AND ADULTS: Insights from Key Stakeholders in Mozambique, Southern Africa
Preprint
Abstract
Tuberculosis (TB) remains a major global health challenge, particularly in low- and middle-income countries such as Mozambique. To address this burden, promising new preventive TB vaccines targeting adolescents and adults are currently in phase III efficacy trials. This study aimed to assess stakeholders’ perspectives on priority high-risk groups, the challenges in reaching them, and potential strategies for delivering a TB vaccine. We conducted a qualitative study using semi-structured interviews with members of the National TB Program, the National Immunization Program, and the National Immunization Technical Advisory Group. Data were collected between March and July 2024. Our findings suggest that a TB vaccine program in Mozambique should prioritize individuals with comorbidities, especially those living with HIV or diabetes, and close contacts of TB patients, followed by healthcare workers, miners, and incarcerated populations. Although uptake is expected to vary across groups, relatively high coverage was anticipated among people living with HIV, TB contacts, and older adults, as well as healthcare workers, incarcerated individuals, formal miners, and in-school adolescents. To improve uptake, campaign-based strategies using mobile brigades were considered promising approaches to expand coverage. Stakeholder perspectives highlight the importance of prioritizing high-risk groups and adopting context-specific delivery strategies to support the effective introduction of a TB vaccine in Mozambique. Clinical trial number: not applicable.Keywords
This publication has 16 references indexed in Scilit:
- Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptabilityVaccine, 2026
- Non-adherence and its predictors among pediatric household contacts on tuberculosis preventive therapy in the 3HP era: A multicenter observational studyTherapeutic Advances in Infectious Disease, 2026
- Identifying context-specific drivers of routine childhood immunisation dropout in Mozambique and Malawi: a secondary thematic analysis of qualitative community-based participatory research dataBMJ Open, 2025
- Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trialThe Lancet HIV, 2025
- Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b–2a, double-blind, dose-escalation, randomised controlled trialThe Lancet Global Health, 2025
- The critical role of new tuberculosis vaccines in achieving the WHO 2035 End TB targetIJID Regions, 2025
- The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling studyThe Lancet Global Health, 2023
- Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccinesPLOS Global Public Health, 2022
- Unmasking the hidden tuberculosis mortality burden in a largepost mortemstudy in Maputo Central Hospital, MozambiqueEuropean Respiratory Journal, 2019
- High tuberculosis burden among people living with HIV in southern MozambiqueEuropean Respiratory Journal, 2014